Drug Discovery · Cambridge, MA · Founded 2022 · Privately Held (backing)
Developer of in vivo genetic medicines designed to enable precise insertion of therapeutic genetic material within the human genome. Stylus Medicine is based in Cambridge, MA and was founded in 2022. It was valued at $114 million at its early-stage round in May 2025, the last priced event on record. It has raised $93 million across 1 recorded round; the latest was an $85 million Series A in May 2025.
PMV mark · valuation
$114.0M
Oct 2026
Priced at
its early-stage round
May 2025
Total raised
$93.0M
Last round
Early Stage VC (Series A)
May 2025
No prints on record
No secondary trades in Stylus Medicine shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Stylus Medicine with a free account
·The complete investor list: 12 names
·Watch Stylus Medicine: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Stylus Medicine stock.
